Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Church & Dwight Claims Marketplace Advantage With Value Pricing

This article was originally published in The Tan Sheet

Executive Summary

Church & Dwight relies on a recession-resistant portfolio, innovation, increased marketing and expanded distribution to continue growing despite reduced consumer spending. CEO James Craigie cautions competitor P&G against a price war, and promises to “hold our price caps.”

You may also be interested in...



Church & Dwight Hopes Oral Care, Orajel Reverse Personal Care Slump

The firm seeks to make personal care a growth engine again, hoping single-dose Orajel can overcome competition and FDA concerns about benzocaine overdosing.

P&G Plans More Price Cuts In 2013, Defends Savings Plan

Procter & Gamble will slash prices on some products in the short term to halt U.S. market share erosion in categories where competitors did not previously raise prices. On the firm’s Q4 earnings call, executives defended their bullish growth and savings projections.

P&G Slashes Guidance, Promises Sharper Focus, Bigger Innovations

The firm makes “necessary adjustments” to achieve more balanced growth across its markets and product categories, CEO Bob McDonald says. But Wall Street may not be reassured, as analysts are frustrated with P&G for not better defending against macroeconomic challenges and fixing internal structural issues.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS106454

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel